Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne H Cross

Showing results (161-170 of 194) with videos related to

Pageof 20
Sort By:
ACS Chemical Neuroscience|September 13, 2021
<i>In</i><i>Vitro</i> and <i>In Vivo</i> Investigation of S1PR1 Expression in the Central Nervous System Using [<sup>3</sup>H]CS1P1 and [<sup>11</sup>C]CS1P1Hao Jiang, Sumit Joshi, Hui Liu, et al.
Frontiers in Immunology|April 18, 2022
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II TrialsTjalf Ziemssen, Douglas L Arnold, Enrique Alvarez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2022
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and IIJutta Gärtner, Stephen L Hauser, Amit Bar-Or, et al.
Neurology and Therapy|May 3, 2022
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2021
CD11c<sup>+</sup>CD88<sup>+</sup>CD317<sup>+</sup> myeloid cells are critical mediators of persistent CNS autoimmunityNavid Manouchehri, Rehana Z Hussain, Petra D Cravens, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2013
Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1Stefano Angiari, Barbara Rossi, Laura Piccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 27, 2013
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosisChiara Fenoglio, Elisa Ridolfi, Claudia Cantoni, et al.
Blood|July 17, 2010
ITAM signaling in dendritic cells controls T helper cell priming by regulating MHC class II recyclingDaniel B Graham, Holly M Akilesh, Grzegorz B Gmyrek, et al.
Plos One|March 2, 2011
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitisNancy L Monson, Petra Cravens, Rehana Hussain, et al.
Pageof 20

Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
ACS Chemical Neuroscience|September 13, 2021
<i>In</i><i>Vitro</i> and <i>In Vivo</i> Investigation of S1PR1 Expression in the Central Nervous System Using [<sup>3</sup>H]CS1P1 and [<sup>11</sup>C]CS1P1Hao Jiang, Sumit Joshi, Hui Liu, et al.
Frontiers in Immunology|April 18, 2022
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II TrialsTjalf Ziemssen, Douglas L Arnold, Enrique Alvarez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2022
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and IIJutta Gärtner, Stephen L Hauser, Amit Bar-Or, et al.
Neurology and Therapy|May 3, 2022
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2021
CD11c<sup>+</sup>CD88<sup>+</sup>CD317<sup>+</sup> myeloid cells are critical mediators of persistent CNS autoimmunityNavid Manouchehri, Rehana Z Hussain, Petra D Cravens, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2013
Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1Stefano Angiari, Barbara Rossi, Laura Piccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 27, 2013
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosisChiara Fenoglio, Elisa Ridolfi, Claudia Cantoni, et al.
Blood|July 17, 2010
ITAM signaling in dendritic cells controls T helper cell priming by regulating MHC class II recyclingDaniel B Graham, Holly M Akilesh, Grzegorz B Gmyrek, et al.
Plos One|March 2, 2011
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitisNancy L Monson, Petra Cravens, Rehana Hussain, et al.
Pageof 20